InflaRx Announces That The First Patient Has Been Dosed In Its Phase 3 Study Investigating The Efficacy And Safety Of Vilobelimab In Pyoderma Gangrenosum
Portfolio Pulse from Benzinga Newsdesk
InflaRx has announced that the first patient has been dosed in its Phase 3 study investigating the efficacy and safety of Vilobelimab in Pyoderma Gangrenosum. This marks a significant milestone in the development of the drug.
November 06, 2023 | 12:36 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
InflaRx's announcement of the first patient being dosed in its Phase 3 study for Vilobelimab could potentially boost investor confidence in the company's drug development capabilities.
The initiation of Phase 3 trials is a significant milestone in drug development, often leading to increased investor confidence. This could potentially lead to a short-term increase in InflaRx's stock price.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100